Follow-The-Filings

Security · featured owners

ACAD Acadia Pharmaceuticals Inc.

Health Care COM Equity as of 2026 Q2 among managers we track

  • 1 Owner
  • Max 10.0%
  • $72M
  • 1 reduce 1 exit

ACAD (Acadia Pharmaceuticals Inc.) is held in 1 featured 13F book as of 2026 Q2. Palo Alto Investors is the largest tracked holder by portfolio weight (10.0%). Figures are as-filed 13F, not free float.

Who owns this now

Largest portfolio weights among featured holders · max 10.0% (Palo Alto Investors) · not free-float ownership

  1. Palo Alto Investors reduce 10.0%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
Palo Alto Investors 2026 Q2 10.0% Reduce −0.3% 2,864,096 $72M history
David Witzke - Avidity Partners Management exited 2026 Q2 last 2026 Q1 0.06% Exit −0.06% 12,967 $289K history

1 current · 1 exited last period · options excluded

SEC filings

Recent issuer filings from EDGAR · 11 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 8.01,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
8-K 5.02 Filing Doc
10-K Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 2.02,7.01,9.01 Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 11 rows shown

Filed Form Detail Links
4 Period Aug 5, 2026 Filing Doc
4 Period Jul 29, 2026 Filing Doc
4 Period Jun 26, 2026 Filing Doc
4 Period May 29, 2026 Filing Doc
4 Period May 29, 2026 · 6 forms Filing Doc
4 Period May 26, 2026 Filing Doc
4 Period May 1, 2026 · 2 forms Filing Doc
4 Period Apr 5, 2026 · 2 forms Filing Doc
4 Period Mar 24, 2026 · 5 forms Filing Doc
4 Period Mar 3, 2026 Filing Doc
4 Period Mar 6, 2026 · 4 forms Filing Doc

Updated 5 days ago Source: SEC EDGAR submissions All on EDGAR

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $0.726B $0.958B $1.07B
Gross profit * $684.8M $875.96M $982.51M
Gross margin * 94.3% 91.5% 91.7%
Net income -$61.29M $226.45M $391M
Net margin * -8.4% 23.6% 36.5%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $0.616B $0.938B $1.06B
Total non-current assets * $132.83M $249.44M $502.08M
Total assets $0.749B $1.19B $1.56B
Total current liabilities $254.25M $394.87M $277.11M
Total non-current liabilities * $62.95M $60.09M $59.69M
Total equity $0.432B $0.733B $1.23B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $16.7M $157.72M $109.84M
Cash from investing $32M -$30.54M -$302.56M
Cash from financing $25.13M $6.84M $49.88M
Net change in cash $73.81M $133.93M -$142.82M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders